Cargando…

Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis

BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) represent a distinct hypervascularized tumor entity, often diagnosed at metastatic stage. Therapeutic efficacy of anti-angiogenic multi-kinase inhibitors is frequently limited by primary or acquired resistance in vivo. This study aimed to characte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Egidi, Maren Juliane, Krug, Sebastian, Haybaeck, Johannes, Michl, Patrick, Griesmann, Heidi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575939/ https://www.ncbi.nlm.nih.gov/pubmed/37620408 http://dx.doi.org/10.1038/s41416-023-02389-6

Ejemplares similares

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2020)

The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling
por: Krug, Sebastian, et al.
Publicado: (2021)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2
por: Sperling, Florian, et al.
Publicado: (2022)

Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer
por: Bajbouj, Khuloud, et al.
Publicado: (2022)

Carcinogenesis in transgenic mouse models.
por: Lyon, T
Publicado: (1997)

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
por: Breitenecker, Kristina, et al.
Publicado: (2023)

Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
por: Gotink, Kristy J., et al.
Publicado: (2009)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Correction: Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2020)

Translational Regulation in Hepatocellular Carcinogenesis
por: Bracic Tomazic, Suzana, et al.
Publicado: (2021)

Tyrosine kinase signalling in breast cancer: Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer
por: Andrechek, Eran R, et al.
Publicado: (2000)

Therapeutic effects of axitinib, an anti-angiogenic tyrosine kinase inhibitor, on interstitial cystitis
por: Shin, Jung Hyun, et al.
Publicado: (2023)

CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation
por: Griesmann, Heidi, et al.
Publicado: (2021)

IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2017)

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
por: Zhang, Yazhuo, et al.
Publicado: (2018)

Gastric carcinogenesis: a comprehensive review of the angiogenic pathways
por: Forma, Alicja, et al.
Publicado: (2020)

Gender-specific changes of the gut microbiome correlate with tumor development in murine models of pancreatic cancer
por: Kaune, Tom, et al.
Publicado: (2023)

CUX1—Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors
por: Krug, Sebastian, et al.
Publicado: (2020)

THE RON RECEPTOR TYROSINE KINASE POSITIVELY REGULATES ANGIOGENIC CHEMOKINE PRODUCTION IN PROSTATE CANCER CELLS
por: Thobe, Megan N., et al.
Publicado: (2009)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

Modeling Obesity-Driven Pancreatic Carcinogenesis—A Review of Current In Vivo and In Vitro Models of Obesity and Pancreatic Carcinogenesis
por: Kfoury, Sally, et al.
Publicado: (2022)

Implications of tyrosine phosphoproteomics in cervical carcinogenesis
por: Robinson-Bennett, Bernice L, et al.
Publicado: (2008)

Transgenic rat models for mutagenesis and carcinogenesis
por: Nohmi, Takehiko, et al.
Publicado: (2017)

Epigenetic Deregulation of Protein Tyrosine Kinase 6 Promotes Carcinogenesis of Oral Squamous Cell Carcinoma
por: Hsieh, Yi-Ping, et al.
Publicado: (2022)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Inhibition of mTOR Reduces Anal Carcinogenesis in Transgenic Mouse Model
por: Sun, Zhi-Jun, et al.
Publicado: (2013)

Gastric Carcinogenesis in the miR-222/221 Transgenic Mouse Model
por: Choi, Boram, et al.
Publicado: (2017)

Considerations for skin carcinogenesis experiments using inducible transgenic mouse models
por: Popis, Martyna C., et al.
Publicado: (2018)

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma
por: Canter, Robert J, et al.
Publicado: (2014)

The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
por: Wium, Martha, et al.
Publicado: (2021)

The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by Benzbromarone
por: Tadjuidje, Emmanuel, et al.
Publicado: (2012)

Met Receptor Tyrosine Kinase Signaling Induces Secretion of the Angiogenic Chemokine Interleukin-8/CXCL8 in Pancreatic Cancer
por: Hill, Kristen S., et al.
Publicado: (2012)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart
por: Sala, Valentina, et al.
Publicado: (2016)

The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells
por: Wei, Ning, et al.
Publicado: (2014)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_prqqpi2fc88ir9tn5dudjj1jf0